| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
| Targets |
This intermediate does not have a specific biological target. It is a building block for constructing potent kinase inhibitors. The final drugs may interact with ATP‑binding sites, but the intermediate itself is not biologically active.
|
|---|---|
| ln Vitro |
In vitro, this compound is used in medicinal chemistry to generate libraries of pyridopyrimidine derivatives. Its multiple halogen and heteroaryl groups allow for diverse functionalization via cross‑coupling and nucleophilic substitution. It is especially valuable for anticancer drug discovery.
|
| ln Vivo |
In vivo, it is not a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable. Characterization includes HPLC, NMR, and MS.
|
| Cell Assay |
In vitro cellular assays are not performed on this intermediate.
|
| Animal Protocol |
In vivo animal studies are not conducted.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not available.
|
| Toxicity/Toxicokinetics |
The compound is a laboratory chemical; handle with standard precautions.
|
| Additional Infomation |
7‑Chloro‑6‑fluoro‑1‑(2‑isopropyl‑4‑methylpyridin‑3‑yl)pyrido[2,3‑d]pyrimidine‑2,4(1H,3H)‑dione is a research intermediate for kinase inhibitor synthesis. It is not approved for clinical use.
|
| Molecular Formula |
C16H14CLFN4O2
|
|---|---|
| Molecular Weight |
348.759365558624
|
| Exact Mass |
348.078
|
| CAS # |
2252403-82-8
|
| PubChem CID |
135379087
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
520
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C(=CC2C(NC(N(C=2N=1)C1=C(C)C=CN=C1C(C)C)=O)=O)F
|
| InChi Key |
OXJTVPMAMRSGNT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14ClFN4O2/c1-7(2)11-12(8(3)4-5-19-11)22-14-9(15(23)21-16(22)24)6-10(18)13(17)20-14/h4-7H,1-3H3,(H,21,23,24)
|
| Chemical Name |
7-chloro-6-fluoro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8673 mL | 14.3365 mL | 28.6730 mL | |
| 5 mM | 0.5735 mL | 2.8673 mL | 5.7346 mL | |
| 10 mM | 0.2867 mL | 1.4337 mL | 2.8673 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.